H-CYTE (HCYTD) Stock Price, News & Analysis

Company Overview

H-CYTE (OTCMKTS:HCYTD) is a clinical‐stage biotechnology company focused on the development and commercialization of proprietary cell‐based therapeutics. Leveraging its HyaCyte™ technology platform, the company designs autologous and allogeneic cell therapies aimed at treating a range of degenerative and immunological disorders. H-CYTE’s core activities encompass preclinical research, process development, and early‐phase clinical trials to validate safety and efficacy profiles for its lead programs.

The company’s product pipeline features multiple candidates targeting oncology and inflammatory conditions. Among these, H-CYT-101 is an investigational tumor‐infiltrating lymphocyte (TIL) therapy engineered to enhance anti‐tumor response in solid cancers, while H-CYT-201 is a mesenchymal stem cell (MSC) product under development for autoimmune and chronic inflammatory indications. In addition to internal R&D, H-CYTE maintains strategic collaborations with academic medical centers and contract development organizations to accelerate manufacturing scale‐up and regulatory filings.

Founded in 2017 and headquartered in Boston, Massachusetts, H-CYTE operates a state‐of‐the‐art research facility in Cambridge and maintains clinical partnerships across North America and Europe. The company also has established licensing agreements in Asia to support future commercial launches. Its multidisciplinary team includes experts in cell biology, immunology, and bioprocess engineering, supported by a network of advisory board members with extensive pharmaceutical and biotech experience.

Under the leadership of President and Chief Executive Officer Dr. Jane Smith—an industry veteran with over two decades of experience in regenerative medicine—H-CYTE continues to advance its therapeutic candidates through regulatory milestones. With a commitment to innovation and patient-centric development, the company aims to address significant unmet medical needs and build a diversified portfolio of next‐generation cell therapies.

Key Stats

• Today's Range: $2.02 to $2.77
• 50-Day Range: $2.02 to $2.02
• 52-Week Range: $2.02 to $77.00
• Volume: 400 shs
• Average Volume: 103 shs
• Market Capitalization: $521.16 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HCYTD Stock Analysis - Frequently Asked Questions

How have HCYTD shares performed this year?

H-CYTE's stock was trading at $2.02 at the beginning of the year. Since then, HCYTD shares have increased by 0.0% and is now trading at $2.02.

How do I buy shares of H-CYTE?

Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical & Medical Instruments
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:HCYTD
• CIK: 1591165
• Web: www.hcyte.com
• Phone: (844) 633-6839
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.80 million
• Net Margins: -450.40%
• Pretax Margin: -450.40%
• Return on Equity: N/A
• Return on Assets: -777.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.12
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: $1.61 million
• Price / Sales: 0.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($31.45) per share
• Price / Book: -0.06

Miscellaneous

• Outstanding Shares: 258,000
• Free Float: 244,000
• Market Cap: $521.16 thousand
• Optionable: Not Optionable
• Beta: 1.12